Vasectomy and risk of prostate cancer: population based matched cohort study

Madhur Nayan,Robert J Hamilton,Erin M Macdonald,Qing Li,Muhammad M Mamdani,Craig C Earle,Girish S Kulkarni,Keith A Jarvi,David N Juurlink,Canadian Drug Safety and Effectiveness Research Network (CDSERN)
DOI: https://doi.org/10.1136/bmj.i5546
2016-11-03
BMJ
Abstract:Objective: To determine the association between vasectomy and prostate cancer, adjusting for measures of health seeking behaviour. Design: Population based matched cohort study. Setting: Multiple validated healthcare databases in Ontario, Canada, 1994-2012. Participants: 326 607 men aged 20 to 65 who had undergone vasectomy were identified through physician billing codes and matched 1:1 on age (within two years), year of cohort entry, comorbidity score, and geographical region to men who did not undergo a vasectomy. Main outcomes measures: The primary outcome was incident prostate cancer. Secondary outcomes were prostate cancer related grade, stage, and mortality. Results: 3462 incident cases of prostate cancer were identified after a median follow-up of 10.9 years: 1843 (53.2%) in the vasectomy group and 1619 (46.8%) in the non-vasectomy group. In unadjusted analysis, vasectomy was associated with a slightly increased risk of incident prostate cancer (hazard ratio 1.13, 95% confidence interval 1.05 to 1.20). After adjustment for measures of health seeking behaviour, however, no association remained (adjusted hazard ratio 1.02, 95% confidence interval 0.95 to 1.09). Moreover, no association was found between vasectomy and high grade prostate cancer (adjusted odds ratio 1.05, 95% confidence interval 0.67 to 1.66), advanced stage prostate cancer (adjusted odds ratio 1.04, 0.81 to 1.34), or mortality (adjusted hazard ratio 1.06, 0.60 to 1.85). Conclusion: The findings do not support an independent association between vasectomy and prostate cancer.
What problem does this paper attempt to address?